Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
20
pubmed:dateCreated
2009-10-15
pubmed:abstractText
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we recently identified as inhibitors of thioredoxin glutathione reductase (TGR), a selenocysteine-containing flavoenzyme required by the parasite to maintain proper cellular redox balance. Through systematic evaluation of the core molecular structure of this chemotype, we define the essential pharmacophore, establish a link between the nitric oxide donation and TGR inhibition, determine the selectivity for this chemotype versus related reductase enzymes, and present evidence that these agents can be modified to possess appropriate drug metabolism and pharmacokinetic properties. The mechanistic link between exogenous NO donation and parasite injury is expanded and better defined. The results of these studies verify the utility of oxadiazole-2-oxides as novel inhibitors of TGR and as efficacious antischistosomal agents.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1520-4804
pubmed:author
pubmed:issnType
Electronic
pubmed:day
22
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6474-83
pubmed:dateRevised
2011-9-29
pubmed:meshHeading
pubmed-meshheading:19761212-Animals, pubmed-meshheading:19761212-Biological Availability, pubmed-meshheading:19761212-Drug Discovery, pubmed-meshheading:19761212-Enzyme Inhibitors, pubmed-meshheading:19761212-Humans, pubmed-meshheading:19761212-Inhibitory Concentration 50, pubmed-meshheading:19761212-Models, Molecular, pubmed-meshheading:19761212-Multienzyme Complexes, pubmed-meshheading:19761212-NADH, NADPH Oxidoreductases, pubmed-meshheading:19761212-Nitric Oxide, pubmed-meshheading:19761212-Oxadiazoles, pubmed-meshheading:19761212-Protein Conformation, pubmed-meshheading:19761212-Rats, pubmed-meshheading:19761212-Schistosoma, pubmed-meshheading:19761212-Schistosomiasis, pubmed-meshheading:19761212-Schistosomicides, pubmed-meshheading:19761212-Solubility, pubmed-meshheading:19761212-Structure-Activity Relationship, pubmed-meshheading:19761212-Substrate Specificity
pubmed:year
2009
pubmed:articleTitle
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis.
pubmed:affiliation
NIH Chemical Genomics Center, National Human Genome Research Institute, NIH, 9800 Medical Center Drive, MSC 3370, Bethesda, Maryland 20892-3370, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural